BNTX

$96.69-$2.17 (-2.20%)live

Compare

Change$-262.49

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held · Bookmarked

0 · 0

portfolios · users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$24.8B

251M shares

52-week range

$79.52 – $124.00

39% from low

Exchange

NASDAQ

ADRC

P/S (TTM)

9.3

EV / FCF (TTM)

29.1

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$1.8B	-32.5%	$-5.69	$-6.14–$-5.24	—	9
2027	$1.8B	-1.4%	$-5.73	$-6.91–$-4.56	—	9
2028	$2.4B	+30.9%	$-3.89	$-10.47–$1.14	—	13
2029	$2.1B	-10.8%	$-4.41	$-5.70–$-3.06	—	10

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 6 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-04	$-2.40	$-3.70	-54.3%
2026-05-05	$-2.54	$-2.43	+4.4%
2026-03-10	$-0.22	$-1.44	-556.7%
2025-11-03	$-1.12	$-0.14	+87.5%
2025-08-04	$-2.69	$-1.82	+32.3%
2025-05-05	$-2.48	$-1.82	+26.5%
2025-03-10	$0.46	$1.15	+148.7%
2024-11-04	$-1.74

DCF fair valuemodel estimate

Intrinsic value

$47.97

Price

$96.69

Implied downside

-50%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
BNTXBioNTech SE	$98.86	+2.20%	$24.8B	—
BIIBBiogen Inc.	$217.36	+0.10%	$32.1B	—
DXCMDexCom, Inc.	$84.68	+1.99%	$32.0B	—
GMABGenmab A/S	$32.65	+0.55%	$20.0B	—
INCYIncyte Corporation	$122.19	+0.59%

BioNTech SE American Depositary Share

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

www.biontech.de

Employees: 7,807
IPO / List date: Oct 10, 2019

Held by traders on TradeandTell

No one on the platform currently holds BNTX.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Bridgewater Associatesas of 2025-12-31	4,927	$469.1K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded BNTX yet.

$BNTX chatter on StockTwits

Cooler than Cool@mollielatham4h
$BNTX the market is a scam
View on StockTwits ↗
Steve Richter@htw7448Bullish11h
$BNTX ich hoffe diese Moderna Klitsche voller Dampfplauderer geht bald unter. ;)
View on StockTwits ↗
JJ Hedge@AIIAAIIA_88Bullish14h
$BNTX LOL The “market” will keep this between 97.50 and 100 this week, I bet. It will move up when the “market” movers are ready to profit from, eventually. Sooner than later, I hope. Fair value (for now) is 180+. JMO
View on StockTwits ↗
Steve Richter@htw7448Bullish17h
$BNTX of course the dhitshiw continues. I ll add more till the crookheads are surrounded by positive facts.
View on StockTwits ↗
Sergey MD@Sergey_stockdoc18h
$BNTX Investors on here are so ridiculous. They are upset that Moderna moved but this didn’t. What does this tell us? It tells us that it’s not the science that moved Moderna, because if it was it should have never hit the $20’s. It was a short squeeze possibly caused by retailers accumulating on news and some short covering. So in time that will come down from the sky and meet this company in valuation. Based off the price action of BioNtech it is appropriately priced because its sales are years away from producing fruit, and even then its execution risk. So with that all being said, expect a gradual grinding of BNTX at current levels for the foreseeable future and Moderna to come back below $100 again because science alone isn’t enough, it’s cash flows that matter more and both are in negative territory.
View on StockTwits ↗
Steve Richter@htw7448Bullish21h
$BNTX also the title of the oral presentation today was: “The breaktrough immunotherapy for patients with nscls/sclc”. And medical scientists do not tend to overrate things. But first investors should get their 3 brain cells together!
View on StockTwits ↗
Steve Richter@htw7448Bullish22h
$BNTX is not Moderna, Moderna is great because its US. They can flip a penny and the investors give it 50% plus. Meanwhile BNTX is very close to deliver a keytruda sucessor with 30 billion annual rev, but hey who cares! Fucking US fanboys should wake up!
View on StockTwits ↗
Eurofighter@Eurofighter1d
$BNTX if Moderna had the same news it would have popped 30% at least
View on StockTwits ↗
Crider@Crider1d
$BNTX any news?
View on StockTwits ↗
Dick@DrDickTracy1d
@AIIAAIIA_88 @eightytwentie I think there's few from Wall St. at that conference. By then, once the conference concludes, $BNTX will issue a press release? Not sure if it makes complete sense to issue a press release earlier.
View on StockTwits ↗
Dick@DrDickTracy1d
$BNTX Still have their last presentation coming in in about 6-7 hours Phase 3 trial results Pop pop pop
View on StockTwits ↗
AV@wintogether1d
$BNTX disappointing price action today, but happy for the patients. Hope the company helps improve the standard of care and realizes a good value in the long run.
View on StockTwits ↗
Inno-Cents X@Pope_of_ProfitBullish1d
$BNTX hm might actually be an entry
View on StockTwits ↗
John Beidle@taxplanrBearish1d
The zionist's were covering up COVID vaccines deaths also $MRNA $PFE $BNTX https://www.instagram.com/reel/DdReFG2xP_B/?stkn=ZmRlMnU4bGRwb2gz
View on StockTwits ↗
Michael Schweizer@Moin771d
$BNTX See you again at $120 🤑
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.